

Index

- A**
- Acetate, 124–125
 - Acetylation, 118–120
 - Acetyl-CoA
 - fatty acid and sterol biosynthesis, 153
 - histone acetylation, 118–119
 - metabolism and metabolic signaling, 122–123
 - synthesis, signaling pathways for, 107–108
 - use in TCA, 153
 - Acidification of tumor microenvironment, 34–37
 - Adenoviral infection, 89–90
 - Aerobic glycolysis
 - biomass synthesis, 139–140
 - driven by oncogenic signaling pathways, 104
 - explanations for benefits in cancer, 136–138
 - historical studies, 3–5, 65
 - NADH/NAD⁺ metabolism, 139, 141
 - in nonproliferative contexts, 137
 - unifying explanation in different contexts, 140–141
 - Warburg effect, 136–138, 147–148
 - AKT
 - in growth signaling networks, 98–103, 105, 108, 110
 - historical studies, 9–12
 - oncogenic control of metabolism, 68–70, 72, 74
 - SREBP activation, 206, 210
 - Alanine, in tumor microenvironment, 354
 - α KG-dependent dioxygenases, 268–269
 - Amino acids
 - competition for, 363
 - dietary interventions as cancer therapy, 387–388
 - uptake and signaling pathways, 101–102
 - Amino acid synthesis
 - metabolic imaging, 31–33
 - nonessential (NEAA), 106–107, 288
 - Ammonia, and nitrogen recycling, 152
 - Ammonium, reincorporating to support growth, 75
 - AMP-activated protein kinase (AMPK)
 - as energy sensor and regulator of catabolism, 121–122
 - in low oxygen conditions, 334
 - Anabolism
 - cofactor and precursor synthesis, 105–108
 - metabolic imaging, 31–34
 - mTOR as regulator of, 121
 - Anaplerosis, 70, 101, 105, 155, 316, 399
 - Anemia of cancer, 257–258
 - Antigen presentation, inhibition of, 348–349
 - Antioxidants, 294–295
 - Apoptosis, (R)-2-hydroxyglutarate effect on, 178
 - Arginase 1 (ARG1), 222–224, 226–229, 231, 353
 - Arginase 2 (ARG2), 222, 224, 229
 - Arginine
 - maintenance of circulating by autophagy, 353–354
 - and urea cycle enzymes, 222–224, 227–231
 - Argininosuccinate synthase 1 (ASS1), 221–228, 230–231
 - Argininosuccinate lyase (ASL), 221–226
 - Asparagine, 152, 388
 - Aspartate
 - levels in hypoxia, 326
 - as limiting metabolite for cancer, 151–152
 - ATP
 - ATP/ADP ratio, 135
 - excess in many cancers, 137–138
 - production rate, 137–138
 - ATP citrate lyase (ACLY), 72, 87, 103, 108, 122, 124, 326, 331
 - Autophagy
 - antigen presentation, inhibition of, 348–349
 - genomic stability, 350
 - host (tumor-cell nonautonomous), 351–355
 - immune response, inhibition of antitumor, 348–349
 - immunotherapy effectiveness suppressed by, 355
 - inflammation suppression, 351, 354–355
 - in low oxygen conditions, 333–334
 - metabolic pathways, support of, 347–348
 - metastasis, role in, 351
 - NAD⁺ level maintenance, 14
 - in normal tissue, 352–353
 - overview, 345–346
 - oxidative stress, suppression of, 350
 - p53 inhibition, 350
 - as source of bioenergetic substrates, 76
 - in the stroma, 310–311
 - tumorigenesis, promotion of, 347–351
 - tumor-intrinsic, 346–351
 - tumor microenvironment modulation, 349
 - up-regulation by oncogenic events, 346–347
- B**
- Bicarbonate, molecular imaging, 36
 - Bioenergetics, and signaling pathways, 103–105
 - Biomarkers, metabolites as diagnostic, 196–197

Index

- Biomass production
 aerobic glycolysis, 135, 139–140
 NADH/NAD⁺ ratio, 139–140
 oxidation reactions, role of, 139
- Branched-chain amino acid transaminases (BCATs), 177
- C**
- CAD enzyme, 225–226
- Calorie restriction, 386–387
- Cancer-associated fibroblasts (CAFs), 229–230, 310–317, 335
- Cancer progression, metabolic basis of, 415–416
- Carbamoyl phosphate synthetase 1 (CPS1), 221, 224–226, 230–231
- Carnitine-palmitoyl transferase 1 (CPT1), 209, 313
- Catabolism, AMPK as regulator of, 121–122
- CD36, 102, 208, 213, 312, 365, 371–372, 387
- Cell-intrinsic growth and survival, signaling pathways for, 97–100
- Cell metabolism
 as context dependent, 91
 next questions and challenges in study of, 90–91
 unifying themes, 84
- Cellular stress response pathways, fatty acid and cholesterol metabolism interactions with, 203–214
- Central carbon metabolism
 fiber intake effects on, 390
 oncogenic control of metabolism, 70–74
- Chemical exchange saturation transfer (CEST), 26–27, 36
- Chimeric antigen receptor-modified T (CAR-T) cells, 372–374
- Cholesterol
 cellular stress response pathways, interactions with, 203–214
 functions, 204
 mevalonate pathway, 206–207
 targeting metabolism for cancer treatment, 212–214
 transcriptional regulation of synthesis, 204–205
- Cisplatin, 226
- Citrulline-NO cycle, 222
- c-myc*, 70, 72, 74
- CoA synthesis, signaling pathways for, 107–108
- Cofactor synthesis, signaling pathways for, 105–108
- Collagen, 316–317
- Copper, 269–271
- Cori cycle, 5, 7
- Crabtree effect, 5–6
- Cytochrome *c* oxidase, (R)-2-hydroxyglutarate effect on, 178
- D**
- Deferoxamine, 258
- Dehydroascorbic acid (DHA), in metabolic imaging, 34
- Desorption electrospray ionization (DESI), 50–51, 54
- Developmental pliancy, 87
- Diet
 amelioration of neuropathy progression, 85
 antioxidants, 295
 cancer prevention, 383–384
 ketogenic, 14, 126, 386
 low-fat, 383–384
 as means to control cell metabolism in vivo, 84–85
 methionine restriction in viral infection, 90
 microbiome response to, 390
 principles and molecular metabolism, 382–383
- Dietary interventions as cancer therapy
 amino acid metabolism, 387–388
 fasting, calorie restriction, and glucose metabolism, 386–387
 lipid metabolism, 387
 micronutrients, 388–389
 overview, 384–386
- Dihydroorotate dehydrogenase (DHODH), 10, 152, 156, 207
- Dioxygenases
 αKG-dependent, 268–269
 oncometabolites as inhibitors of, 186–188
- Dissolution dynamic nuclear polarization (dDNP), 23
- DNA
 damage induced by oncometabolites, 195
 damage repair defective in *IDH*-mutant cancer cells, 177
 demethylation, 121, 268
 methylation, 120, 186, 268
 synthesis in growth signaling networks, 108–109
- E**
- EGLN enzymes, 176
- Electron paramagnetic resonance imaging (EPRI), 37
- Electron transport chain (ETC)
 disruptions or dysfunctions in, 149
 essential functions of, 150–152
 in low oxygen conditions, 325–326
 reliance of cancer cells, 148–154
 targeting for cancer therapy, 156–157
- Embryonic development
 glucose uptake, 87–89
 lessons from studying cancer metabolism, 87–89
 role of diet in regulating, 84
 role of maternal health, 88–89
- Energy charge, 122
- Energy sensor, AMPK as, 121–122
- Epstein-Barr virus (EBV), 89–90
- ER stress, 206, 210, 213, 332–333
- Extracellular pH, metabolic imaging, 34–37
- Extracellular signal-regulated kinase (ERK)
 in growth signaling networks, 99, 106, 108–109
 (R)-2-hydroxyglutarate induction of, 179

- F**
- Farber, Sidney, 3, 15
 - Fasting, 386
 - Fatty acid metabolism
 - cellular stress response pathways, interactions with, 203–214
 - as driver of ferroptosis resistance, 209–212
 - targeting for cancer treatment, 212–214
 - via β -oxidation, 209
 - Fatty acids
 - functions, 204
 - metabolic cross talk in TME, 125–126
 - short chain, 125
 - uptake and oxidation as drivers of metastasis formation, 207–209
 - Fatty acid synthase (FASN), 206, 212–213, 331
 - Fatty acid synthesis
 - in cell growth and stress resistance, 206
 - as (R)-2-hydroxyglutarate target, 173–175
 - metabolic imaging, 31
 - transcriptional regulation, 204–205
 - Fermentation
 - ATP generation in anaerobic conditions, 133
 - of glucose to ethanol, 137
 - of glucose to lactate, 148
 - independent NAD^+ regeneration, 141
 - pyruvate to ethanol, 140
 - pyruvate fate during nonphotosynthetic growth, 140
 - pyruvate to lactate, 140
 - role in redox metabolism and ATP generation, 134
 - sustaining redox balance and glycolytic flux, 136
 - Ferritin, 259, 262–263
 - Ferritinophagy, 259, 263
 - Ferroportin, 263–264
 - Ferroptosis, 209–212, 293–294, 296, 330–331
 - Fluorescence-activated cell sorting (FACS), 54, 91
 - Fluorodeoxyglucose PET (FDG-PET), 134, 147
 - Folate, 388–389
 - Fumarate
 - accumulation of, 155, 186
 - nonenzymatic oncometabolic role of, 195–196
 - Fumarate hydratase (FH)
 - biochemistry and pathophysiology, 188–189
 - deficient cancers, 155, 185–192, 195–197
 - Future of cancer metabolism research
 - metabolic basis of cancer progression, 415–416
 - metabolic compartmentation in cancer, 414–415
 - next-generation approaches to metabolic therapy, 416–417
- G**
- Gain-of-function alterations in proto-oncogenes, 66
 - Gas cluster ion beam (GCIB) mass spectrometry, 50
 - Genomic stability, 350
- Glucose**
- competition between cancer and immune cells, 362–363
 - metabolic cross talk in TME, 124–125
 - metabolism in hypoxia, 329
 - molecular imaging, 23–27
 - role in metabolism, 134–136
 - uptake in growth signaling networks, 100–101
 - utilization in different embryonic compartments, 88
- Glucose chemical exchange saturation transfer (gluco-CEST), 26–27**
- Glucose transporters (GLUTs)**
- Akt signaling, 68
 - in growth signaling networks, 100, 102
 - metabolic imaging, 23, 25–26
- Glutamate**
- dietary supplementation, 388
 - production suppression by (R)-2HG, 177
 - as therapeutic target, 190
- Glutamine**
- competition for, 363–364
 - historical studies, 3, 8–10, 12, 15
 - molecular imaging, 29–31
 - oncogenic control of metabolism, 70, 74–75
 - as therapeutic target, 297
- Glutaminolysis, metabolic imaging, 29**
- Glutathione (GSH)**
- imaging, 33–34
 - NRF2 effect on, 283, 287–288
 - ROS control, 330–331
 - targeting pathway, 296
- Glycine cleavage system, 242–243**
- Glycine-deficient diet, 85**
- Glycogen, 330**
- Glycolysis. *See also* Aerobic glycolysis**
- ATP production, 133, 135–138
 - biomass production, 135
 - growth signal-associated remodeling of, 70–72
 - in hypoxia, 329
 - metabolic imaging, 23–31
 - role in redox metabolism and ATP generation, 134
 - substrates for posttranslational modifications, 366
- Growth factor-independent growth, 96**
- Growth signaling networks, 95–111. *See also* Signaling pathways**
- H**
- Heme, 267, 293–294
 - Hepatic progenitor cells, 86
 - Hepcidin, 257
 - Hexokinases, 12–13, 68, 103
 - HIF. *See* Hypoxia-inducible factor (HIF)
 - High-throughput single-cell metabolomics (hi-scMet), 54
 - Histone deacetylases (HDACs), 119, 126

Index

- Histone demethylases, 121
- Histones
 - acetylation, 118–120
 - deacetylation, 119–120
 - demethylation, 121, 268
 - lactylation, 125
 - methylation, 120–121, 366
- Historical perspective
 - cancer metabolism controversies, 5–8
 - early concepts of cancer biology, 2–3
 - emerging technologies, 4
 - introduction, 1–2
 - metabolic therapy and lessons learned, 12–15
 - oncogenes and tumor suppressors, 8–10
 - oncogenic alterations of metabolism, 11
 - T-cell activation and effect of diet on tumor metabolism and fate, 13
 - Warburg, Otto, 1–8, 185
 - Warburg effect, 5–9, 12, 147
- Horizontal transfer, 149
- Human cancer, metabolic reprogramming in, 397–410
- Hyaluronic acid, 317
- 2-hydroxyglutarate (2-HG), molecular imaging of, 29–31
- (R)-2-hydroxyglutarate
 - cancer-associated production, 167–176
 - DNA damage repair as target, 177
 - EGLN enzymes as target, 176
 - JmjC-KDM enzymes as target, 175–176
 - non-cell-autonomous effects, 178–179
 - in normal cellular metabolism, 168
 - as oncometabolite, 170–171
 - redox homeostasis, defective, 177
 - TET enzymes as target, 173–175
 - toxic effects on mitochondrial function, 172
 - tumor-promoting targets, 173–176
- Hypermethylation, 121–122, 186–188, 193–195, 287
- Hypoxia
 - alternative fuel sources use during, 152–153
 - autophagy, 333–334
 - cancer metabolism, 323–335
 - ER stress control, 332–333
 - glucose metabolism, 329
 - 2-hydroxyglutarate role in response, 168
 - immunometabolic maladaptations, 364
 - lipid metabolism, 331–332
 - metabolic imaging, 37
 - metabolic pathway adaptations in response to, 326
 - metabolic rewiring of tumor stroma by hypoxia, 335
 - mitochondrial metabolism, 325–327
 - mitochondrial quality control, 327–329
 - nutrient scavenging, 333–334
 - nutrient sensing, 334
 - pseudohypoxia, 186–188, 193, 195, 269
- Hypoxia-inducible factor (HIF)
 - in growth signaling networks, 99–100, 103–104
 - historical studies, 9–11
 - 2-hydroxyglutarate effect on, 168
 - iron role in regulation of, 268–269
 - under limiting oxygen conditions, 323–335
 - pseudohypoxia, 186–188, 193, 195
 - reactive oxygen species (ROS) relationship, 138, 187–188, 283
 - tumor-associated macrophages, 367–369
- I**
- Imaging tumor metabolism
 - magnetic resonance spectroscopy/imaging (MRS/MRI), 22–23
 - metabolic targets, 23–37
 - positron emission tomography (PET), 21–22
- Immune cells
 - cross talk with tumor cells, 227–229
 - metabolism of tumor-infiltrating, 367–374
- Immune response
 - autophagy inhibition of antitumor, 348–349
 - in hypoxia, 335
 - NRF2 suppression of antitumor, 289–290
- Immunometabolic maladaptations, 361–374
- Immunopurification
 - of mitochondria (MITO-IP), 57–59
 - rapid organellar, 58
- Immunotherapy, 355, 374
- Inflammation, autophagy suppression of, 351, 354–355
- Ion mobility spectrometry, 51–52
- Iron
 - cellular iron regulation, 259–269
 - dietary iron overload and cancer, 258
 - heme, 267, 293–294
 - in low oxygen conditions, 330–331
 - non-heme iron proteins, 268–269
 - regulation in NRF2-activated cancers, 293–294
 - systemic iron regulation, 256–258
 - transferrin-dependent uptake, 260–262
 - transferrin-independent uptake, 260–261
 - uses, 255
- Iron chelators, 258
- Iron regulatory proteins (IRPs), 259, 264–266, 294
- Iron–sulfur clusters, 266–267, 331
- Isocitrate dehydrogenase (IDH)
 - metabolic imaging, 29–31
 - 2-oxoglutarate production, 166–167
- Isocitrate dehydrogenase (IDH) mutations
 - cancer types associated with, 167
 - frequency of arginine substitutions in tumors, 172
 - gain-of-function, 29, 86–87, 165–166
 - (R)-2-hydroxyglutarate production, 167–176
 - metabolic vulnerabilities induced by, 176–178
 - overview, 165–166
 - patterns in different cancers, 171–173

tumor-promoting targets of (R)-2HG, 173–176
variant allele frequency (VAF), 178
Isotope tracing, in spatial metabolomics, 54

J

JmjC-KDM enzymes, 175–176

K

KEAP1

cysteine modification by oncometabolites, 286
epigenetic suppression of *KEAP1* gene, 287
interaction with NRF2, 286

KEAP1-NRF2 system, 284–290

Ketone bodies, 126

KRAS

intrahepatic cholangiocarcinoma, 86–87
oncogene silencing, 316
oncogenic control of metabolism, 68–70, 72,
74, 76

Krebs, Hans, 2–3, 8

L

Lactate

accumulation in TME, 364
metabolic cross talk in TME, 124–125
molecular imaging, 27–28
sources of, 153
as TCA fuel, 152

Lactate dehydrogenase (LDH)

in growth signaling networks, 104
historical studies, 9
inhibition of, 189
metabolic imaging, 27–28
MYC effect on, 138
NAD⁺ regeneration, 150

Lipid metabolism

dietary interventions as cancer therapy, 387
in low oxygen conditions, 331–332
paracrine regulation of, 311–312

Lipid peroxidation, 196, 209–213, 296, 330, 367, 371,
384

Lipids. *See also* Cholesterol; Fatty acids

acquisition in growth signaling networks, 102
classification, 203
immunosuppressive TME, 364–365
metabolic cross talk in TME, 125–126
synthesis in growth signaling networks, 103, 105,
109–111

Liver X receptors (LXRs), 206, 213

L/LAT1 transporter, 69–70

Loss-of-function alterations in tumor suppressors, 66

Lysine acetyltransferase (KAT), 119

Lysosome immunopurification (LYSO-IP), 57

LysoTag, 57, 59

M

Macromolecular synthesis, signaling pathways for,
108–110

Macrophages, tumor-associated, 367–369

Macropinocytosis, 101–103, 152, 310–311, 333

MacTel, 85

Magnetic resonance spectroscopy/imaging (MRS/
MRI)

metabolic imaging, 21–38
overview, 22–23

Malate-aspartate shuttle (MAS), 148

Mammalian embryonic development. *See* Embryonic
development

Mass spectrometry

organellar metabolomics, 57
single-cell metabolomics, 54
spatial metabolomics, 50–52

Matrix-assisted laser desorption and ionization
(MALDI), 50–52, 54

Meat, cancer link to, 384

Mechanistic biology, 390–391

Mechanistic target of rapamycin (mTOR)

AMPK as regulator of, 122
autophagy inhibition, 346–347
in growth signaling networks, 99–101, 103, 106–111
in low oxygen conditions, 334
nutrient sensing, 90, 121
oncogenic control of metabolism, 74–76
regulator of anabolism, 121
SREBP activation, 204–206, 210

Metabolic compartmentation in cancer

among different cell types, 414–415
between tumor and distant organs, 415
within cells, 414

Metabolic heterogeneity, 53

Metabolic networks, control by signaling pathways,
95–111

Metabolic pathways, autophagy support of, 347–348

Metabolic remodeling, 189–191

Metabolic reprogramming in human cancer, 397–410

Metabolic scavenging, 307–308

Metabolic signaling

covalent, 118–121
introduction, 117
noncovalent, 121–122
paracrine regulation, 313–316
principles, 117–122

Metabolic signaling in cancer

acetyl-CoA metabolism, 122–123
cross talk in tumor microenvironment, 123–126
emerging aspects of, 126–127
one-carbon metabolism, 123–124
overview of mechanics, 122

Metabolic signals, properties of, 117–118

Metabolic targets, imaging, 23–37

Index

- Metabolites
 - as diagnostic biomarkers, 196–197
 - immune suppressing, 364
 - quantifying 1C metabolism, 245–247
 - Metabolomics
 - organellar, 56–59
 - precision nutrition in oncology, 391
 - single-cell, 53–56
 - spatial, 50–53
 - technology-led advances, 49–59
 - Metals
 - cancer relevance of key metal-regulated proteins and processes, 261
 - copper, 269–271
 - iron, 255–269
 - selenium, 271–272
 - Metastasis
 - autophagy role in, 351
 - fatty acid uptake and oxidation as drivers of, 207–209
 - in oxidative proteome, 283–284
 - Metformin, 155–156, 195
 - Methionine
 - dietary restriction, 387–388
 - metabolic cross talk in TME, 125
 - metabolism in virus infection, 90
 - sulfur metabolism, 291–292
 - Methionine cycle, 243
 - Methotrexate, 250, 388
 - Methylation
 - DNA, 120, 186
 - histones, 120–121, 366
 - hypermethylation, 121–122, 186–188, 193–195
 - Methylation-controlled J protein, 365
 - Methylmalonic acid (MMA), 389
 - Methyltransferases, 120–121
 - Mevalonate pathway, 206–207
 - Michaelis constant (K_m), 118
 - Microbiome, 14–15, 389–390
 - Micronutrients, 388–389
 - Mitochondria
 - essential role of mitochondrial respiration in tumor growth, 150
 - horizontal transfer, 149
 - (R)-2-hydroxyglutarate toxic effects, 172
 - immunopurification of mitochondria (MITO-IP), 57–59
 - metabolism in low oxygen conditions, 325–327
 - nuclear-encoded mitochondrial genes, 155
 - one-carbon (1C) metabolism, 244
 - organellar metabolomics, 56–59
 - overview, 147–148
 - reliance of cancer cells on functional, 148–150
 - retrograde signaling, 155
 - targeting for cancer therapy, 155–157
 - Mitochondrial DNA (mtDNA)
 - homoplasmy and heteroplasmy, 154
 - horizontal transfer, 149
 - mutations in cancer initiation and progression, 154–155
 - replication, 149
 - Mitochondrial quality control, 327–329
 - Mitophagy, 14, 328–329
 - MITO-Tag, 57–59
 - Monocarboxylate transporters (MCTs), 104
 - mRNA translation, role of neuron-derived serine in, 315
 - mTORC1. *See* Mechanistic target of rapamycin (mTOR)
 - Multiomics (paired omics), 55–56
 - MYC
 - 1C metabolism regulation of, 248
 - in growth signaling networks, 99–101, 103–106, 108–111
 - historical studies, 9–12, 14
 - lactate dehydrogenase (LDH), effect on, 138
 - oncogene silencing, 316
 - in virus infection, 89–90
- ## N
- NADH
 - from glycolysis, 135
 - mitochondria metabolism, 148
 - oxidation uncoupling from ATP production, 140–141
 - NADH/NAD⁺ ratio
 - ETC and, 151
 - in low oxygen conditions, 325
 - NRF2 effect on, 289
 - reduced, 138–140
 - NADPH/NADP⁺
 - in fatty acid biosynthesis, 177–178
 - growth signaling pathways, impact of, 105–106
 - in hypoxia, 330
 - Neovascularization, 3, 12
 - Nitric oxide (NO), 222–224, 228–229, 282, 366–367
 - Nitric oxide synthase (NOS), 222, 224, 369
 - Nitrogen budget, 74–75
 - Nitrogen-rich metabolites, accumulation of, 226–227
 - Nonessential amino acid (NEAA) synthesis, 106–107, 288
 - NRF2
 - interaction with KEAP1, 286
 - overview, 284–285
 - posttranscriptional regulation of, 287
 - transcriptional up-regulation of, 286–287
 - in tumor initiation and progression, 289
 - NRF2-activated cancers
 - genetic alterations in, 285–286
 - iron regulation, 293–294
 - metabolic characteristics, 287–289
 - molecular mechanisms leading to, 285
 - tumor microenvironment, 289–290
 - Nucleoside salvage, in metabolic imaging, 33–34

- Nucleotides
 - acquisition in growth signaling networks, 102, 106
 - salvage pathways, 102
 - synthesis in growth signaling networks, 105–106, 108–109, 111
- Nutrient acquisition
 - autonomous and nonautonomous decision-making strategies, 67–68
 - availability competition between cancer and immune cells, 362–364
 - growth signal-associated regulation of uptake, 69
 - oncogenic control of metabolism, 67–70
 - opportunistic strategies, 76
 - signaling pathways, 100–103
- Nutrient scavenging, in low oxygen conditions, 333–334
- Nutrient sensing
 - in low oxygen conditions, 334
 - in metazoans, 68
 - mTOR, 121
 - in unicellular organisms, 67–68
- O**
- Obesity, 383
- Oncogenes
 - discoveries of, 66
 - historical perspective, 2, 8–10, 12
- Oncogene silencing, 315–316
- Oncogenic control of metabolism
 - central carbon metabolism, 70–74
 - glycolysis, growth signal-associated remodeling of, 70–72
 - introduction, 65–66
 - nitrogen budget, 74–75
 - nutrient acquisition, 67–70
 - nutrient uptake, growth signal-associated regulation of, 69
 - opportunistic nutrient acquisition strategies, 76
 - tricarboxylic acid (TCA) cycle, growth-associated remodeling of, 72–73
- Oncometabolites
 - competitive inhibitors of dioxygenases, 186–188
 - DNA damage induced by, 195
 - driven gene-expression changes, 187
 - (R)-2-hydroxyglutarate (2HG), 170–171
 - metabolic pathways that produce, 169
 - nonenzymatic role of fumarate, 195–196
 - NRF2 stabilization induced by, 286
 - therapeutic opportunities due to, 191–195
- One-carbon (1C) metabolism, 123–124
 - across organelles, 242
 - bystander effects, 250
 - compartmentalism of, 244–245
 - dietary interventions as cancer therapy, 387–388
 - dynamic regulation of, 247–248
 - metabolic signaling in cancer, 123–124
 - overview, 239–240
 - quantifying flux and metabolite levels, 245–247
 - targeting, 248–250
 - TCA cycle relation to, 240–244
 - tracing, 245–247
- Orbitrap mass spectrometry, 52
- Organellar metabolomics, 56–59
- Organellar tag, 57–59
- Organotypic tissue cultures (OTCs), 397–410
- Ornithine decarboxylase (ODC), 110
- Ornithine transcarbamylase (OTC)
 - in CAR-T cells, 231, 373
 - urea cycle role, 221–223, 225–226
- OTCs (organotypic tissue cultures), 397–410
- Oxidative pentose phosphate pathway (oxPPP), 105–106, 153
- Oxidative phosphorylation
 - ATP production, 134–137
 - drivers of, 135
 - redox metabolism, role in, 134
- Oxidative stress
 - protein and lipid modifications, 366–367
 - reactive oxygen species and cancer, 282–284, 287, 290–291, 293–294
 - suppressed by autophagy, 350
- 2-oxoglutarate (2OG), 166–167, 170
- Oxygen
 - cancer metabolism under limiting conditions, 323–335
 - molecular imaging, 37
- P**
- p53
 - autophagy inhibition of activation, 350
 - oncogenic control of metabolism, 71–72
 - regulation of SREBP2 by, 207–208
- p62, 313, 350
- Paracrine regulation
 - of cancer cell metabolic signaling networks, 313–316
 - of lipid metabolism, 311–312
- Patient-derived organoids (PDOs), 397, 405–410
- Patient-derived organotypic tissue cultures (PD-OTCs), 397, 401, 410
- Patient-derived tumor xenograft (PDTX), 397, 406, 410
- Pentose phosphate pathway (PPP)
 - in low oxygen conditions, 329–330
 - metabolic imaging, 25–26
 - oxidative (oxPPP), 105–106, 153
- PET. *See* Positron emission tomography
- Phenotypic consequences of cancer metabolism, imaging, 34–37
- pH imaging, 34–37
- Phosphoglycerate dehydrogenase (PHGDH), 72, 168, 240, 248–249, 308, 315, 330

Index

- Phosphoinositide 3-kinase (PI3K)
in growth signaling networks, 98–103, 108, 110–111
historical studies, 9–12
oncogenic control of metabolism, 68–70, 72, 74
- Physiology and disease lessons from studying cancer metabolism, 85
- PI3K-AKT signaling
glucose uptake and glycolysis, enhanced by, 138
in growth signaling networks, 99, 101–103, 108, 110
oncogenic control of metabolism, 68–70, 72, 74
ROS activation of, 283
- PIK3CA*, oncogenic activation of, 98
- Plasticity, metabolic, 12, 307
- Pliancy, 87
- Positron emission tomography (PET)
imaging tumor metabolism, 21–22
metabolic imaging, 21–38
mitochondrial membrane potential, measuring, 150, 156
overview, 21–22
- Posttranslational modifications (PTMs), 117–119, 365–367
- PPAR signaling, 86, 125–126
- Protein
dietary, 387–388
synthesis in growth signaling networks, 108
- Proteomics, single-cell, 53
- Proto-oncogenes, 8, 66
- Pseudohypoxia, 186–188, 193, 195, 269
- PTEN
in growth signaling networks, 98, 102, 110
oncogenic control of metabolism, 66, 68–69, 72, 76
- Pyrimidine biosynthesis, 224–226
- Pyruvate, as TCA fuel, 152
- Pyruvate dehydrogenase (PDH)
in growth signaling networks, 104
metabolic imaging, 28
- Pyruvate kinase, 139
- R**
- RAS, in growth signaling networks, 98–100, 102–103, 106, 108–111
- Reactive oxygen species (ROS)
antioxidants to counteract, 294–295
and autophagy, 350
and cancer, 281–297
in low oxygen conditions, 330
and Warburg effect, 138
- Receptor tyrosine kinases (RTKs)
in growth signaling pathways, 95, 98, 108
regulation of, 66, 68
- Redox homeostasis
defective in *IDH*-mutant cancer cells, 177
fermentation for sustaining, 136
imbalance in cancer initiation and progression, 282–284
metabolic imaging, 34
one-carbon (1C) cycle, 243–244, 248
signaling pathways, 103–105
- Redox metabolism
antioxidants, 294–295
heme and iron metabolism, 293–294
KEAP1-NRF2 system, 284–290
metals, 255–272
overview, 281–282
selenium, role of, 271–272
selenoproteins, 290–291
sulfur metabolism, 291–293
therapeutics targeting, 295–297
- Reductive stress, 14, 283, 288–289, 295–296
- Ribonucleotide reductase, 258, 269
- Ribosomal RNA (rRNA) synthesis, 108–109
- Ribosome biogenesis, 108–109
- S**
- S-adenosylmethionine (SAM)
levels impacted by reprogramming in cancer cells, 123–124
as methyl donor, 110, 120–121
- SCD (stearoyl-CoA desaturase), 206, 210, 213, 327, 332, 387
- Secondary ion mass spectrometry (SIMS)
single-cell metabolomics, 54
spatial metabolomics, 50–51
- Selenium, 271–272
- Selenoproteins, 290–291
- Serine
one carbon metabolism, 387
role of neuron-derived in mRNA translation, 315
- Serine-deficient diet, 85
- Signaling pathways. *See also specific pathways*
adaptive stress, 97
anabolic cofactor and precursor synthesis, 105–108
bioenergetics and redox homeostasis, 103–105
driving cell-intrinsic growth and survival, 97–100
genetic alterations in cancer, 65–77
impact on metabolic hallmarks of cancer cell, 100–110
introduction, 95–97
macromolecular synthesis, 108–110
nutrient acquisition, 100–103
therapeutic perspectives, 110–111
- Single-cell metabolomics, 53–56
- Single-cell transcriptomics, 53, 55
- Spatial metabolomics, 50–53
- SQLE (squalene epoxidase), 207, 212–214
- Squalene, 207, 212
- Squalene epoxidase (SQLE), 207, 212–214
- Stearoyl-CoA desaturase (SCD), 206, 210, 213, 327, 387

- Stem cells, 85–86
- Sterol regulatory element-binding protein (SREBP), 204–209, 214
- Stress resistance, fatty acid synthesis in, 206
- Stroma
- autophagy and macropinocytosis, 310–311
 - catabolic processes, 310–313
 - cross talk of fibroblasts and cancer cells to support oncogene signaling, 315–316
 - metabolic features of nonmalignant cell types in, 308–310
 - metabolic rewiring by hypoxia, 335
 - p62, role of, 313
 - paracrine regulation of lipid metabolism, 311–312
 - paracrine regulation of metabolic signaling networks, 313–316
 - role in cancer metabolism, 307–318
 - supply of nucleic and branched-chain amino acids to cancer cells, 312–313
 - targeting metabolism for cancer therapy, 317–318
 - tumor vasculature, metabolic features and consequences of, 309–310
 - wound-healing mediators as metabolic regulators, 316–317
- Structures for lossless ion manipulations (SLIM), 52
- Succinate, accumulation of, 186
- Succinate dehydrogenase (SDH)
- biochemistry and pathophysiology, 188
 - deficient cancers, 155, 185–197
- Succination, 190, 194, 196
- Sulfur metabolism, 291–293
- Synthetic lethality, 191
- T**
- TCA cycle. *See* Tricarboxylic acid (TCA) cycle
- TCA cycle-dependent cancers, therapeutics for, 185–197
- T cells
- autophagy effect on response, 354–355
 - CAR-T cells, 372–374
 - competition for nutrients with tumor cells, 309
 - (R)-2-hydroxyglutarate impairment of, 179
 - in hypoxia, 335
 - metabolic reprogramming, 369–372
 - side effects of ETC/TCA inhibitors, 157
- Technology, for decoding cancer metabolism with spatial resolution, 49–59
- Ten-eleven translocation (TET) enzymes
- as (R)-2-hydroxyglutarate target, 173–175
 - inhibition by oncometabolites, 186–187, 193–195
 - methylcytosine dioxygenases, 121, 186
 - regulation by iron availability, 268
- Therapeutics
- antioxidants, 295
 - CAR-T cells, 372–374
 - copper-associated, 270–271
 - iron chelators, 258
 - metabolic remodeling, 189–191
 - next-generation approaches to metabolic therapy, 416–417
 - one-carbon (1C) metabolism as target, 248–250
 - redox metabolism as target, 295–297
 - ribonucleotide reductase inhibition, 269
 - stromal metabolism as target, 317–318
 - synthetic lethality, 191
 - for TCA cycle-dependent cancers, 185–197
- Thermal proteome profiling, 127
- Thioredoxin-interacting protein (TXNIP), 68, 100
- Time-of-flight (TOF) mass spectrometry, 51–52
- Tissue homeostasis
- physiology and disease, 85
 - relationship between metabolism and cell state, 84–85
 - role of diet in regulating, 84
 - tissue stem cells and injury repair, 85–87
- TME. *See* Tumor microenvironment
- Transferrin, 260–262
- Tricarboxylic acid (TCA) cycle
- accumulation of intermediates, 152–154, 186
 - activity on cancer compared to normal tissue, 148
 - anaplerosis, 70, 101, 105, 155
 - electron disposal, 136
 - in embryonic development, 87–88
 - growth-associated remodeling of, 72–73
 - in low oxygen conditions, 325–327
 - metabolic imaging, 27–29, 31
 - nutrients that fuel, 152–154
 - one-carbon (1C) metabolism relation to, 240–244
 - overview, 185–186
 - redox balance, 70, 101, 105, 155
 - substrates for posttranslational modifications, 366
 - targeting for cancer therapy, 156–157
 - therapeutics for TCA cycle-dependent cancers, 185–197
 - in virus infection, 89–90
- Tumor microenvironment (TME)
- cross talk of immune and tumor cells, 227–229
 - fatty acids and lipids, 125–126
 - glucose, lactate, and acetate, 124–125
 - immunometabolic maladaptations, 361–374
 - ketone bodies, 126
 - metabolic cross talk, 123–126
 - metabolic imaging, 34–37
 - metabolic milieu as determinant of tumor biology, 308–309
 - metabolic stresses and modifiers, 362–367
 - methionine, 125
 - modulation by autophagy, 349
 - NRF2-activated cancers, 289–290
 - nutrients provided by autophagy, 353–354
 - posttranslational modifications, 365–367

Index

- Tumor microenvironment (TME) (*Continued*)
stroma role in cancer metabolism, 307–318
urea cycle enzymes changes within, 227–230
urea cycle rewiring, cooperation of stromal and tumor cells in, 229–230
- Tumor suppressors
historical perspective, 8–10
loss-of-function alterations in, 66
- Tumor vasculature, metabolic features and consequences of, 309–310
- U**
- Uncoupling proteins, 141
- Unfolded protein response (UPR), 332–333
- Unifying themes in cellular metabolism, 84
- Urea cycle
cross talk of immune and tumor cells via, 227–229
dysregulation in fumarate hydrate-deficient cancers, 190
overview, 221–223
rewiring, cooperation of stromal and tumor cells in, 229–230
- Urea cycle enzymes
changes within tumor microenvironment, 227–230
expression alterations and tumorigenesis, 223
- metabolites in physiological states, 221–223
roles in carcinogenesis, 221–232
- V**
- Virus infection, 84, 89–91
- Vitamins, 86, 388–389
- von Hippel–Lindau (VHL), 186, 212, 269, 323–324, 329
- W**
- Warburg, Otto, 1–8, 65–66, 83, 147, 185
- Warburg effect
aerobic glycolysis and biomass synthesis, 139–140
explanations for benefits in cancer, 136–138, 140–141
historical perspective, 5–9, 12, 147
introduction, 133–134
metabolic imaging, 23, 25, 28, 35
overview, 147–148
role of glucose in metabolism, 134–136
understanding, 133–142
- Warburg manometer, 3–4, 6
- Wound-healing mediators as metabolic regulators, 316–317